Kopran

Kopran PP&E per Employee

The PP&E per Employee of Kopran (KOPRAN.NS) as of Nov 4, 2026 is 7.54 M INR. In the previous year, PP&E per Employee was 6.52 M INR — a change of 15.68% (higher).

PP&E per Employee

7.54 MINR

YoY

15.68%

Last updated:

PP&E per Employee of Kopran is 2025 7.54 M INR. PP&E per Employee of Kopran was 2024 6.52 M INR. It decreases by 15.68% higher compared to the previous year.

The Kopran PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2018
2.84 M INR
Jan 1, 2019
3.29 M INR
Jan 1, 2020
3.37 M INR
Jan 1, 2021
3.71 M INR
Jan 1, 2022
4.46 M INR
Jan 1, 2023
5.55 M INR
Jan 1, 2024
6.52 M INR
Jan 1, 2025
7.54 M INR
The Kopran PP&E per Employee history
YEARPP&E per EmployeeYoY
7.54 MINR+15.68%
6.52 MINR+17.49%
5.55 MINR+24.46%
4.46 MINR+19.94%
3.71 MINR+10.18%
3.37 MINR+2.56%
3.29 MINR+15.96%
2.84 MINR+2.34%
2.77 MINR+5.36%
2.63 MINR+0.80%
2.61 MINR-17.54%
3.16 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kopran Stock analysis

What does Kopran do? Kopran Ltd. generates revenue through the manufacturing and sale of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company produces penicillin-based finished oral dosage forms such as anti-infective, amoxycillin, ampicillin, cloxacillin, and amoxy clauv, as well as non-penicillin-based formulations including macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management, and gastroenterology products. Additionally, Kopran supplies APIs like anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems, and sterile cephalosporins. These products are sold to healthcare providers, distributors, and pharmaceutical companies seeking reliable sources of finished dosage forms and APIs for their own manufacturing processes. The company's product portfolio targets multiple therapeutic segments including anti-infective, cardiovascular, and gastrointestinal treatments. Its formulations cater to both penicillin and non-penicillin-based medical needs, while APIs support a broad range of pharmaceutical applications. Kopran's manufacturing focus on finished dosage forms and APIs enables it to serve the pharmaceutical industry's demand for essential drug components without direct consumer sales. Kopran Ltd. primarily serves pharmaceutical manufacturers and healthcare distributors who require high-quality active ingredients and finished drug products. The firm's production of capsules, injectables, and tablets ensures its offerings meet diverse market needs. By specializing in both formulation and API manufacturing, Kopran positions itself as a key supplier within the pharmaceutical supply chain, providing critical components for various medical treatments. Kopran is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kopran stock

PP&E per Employee of Kopran is 7.54 M INR in 2025.

PP&E per Employee of Kopran changed from 6.52 M INR to 7.54 M INR, representing a 15.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Kopran since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Kopran historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Kopran

All Key Metrics — Kopran